PTT-4256 clinical trials

A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)

This study is testing a new medicine, PTT-4256, for people with solid cancers. Researchers want to see if it's safe, how it works in the body, and if it helps shrink tumours. It's an early-stage study, combining safety checks with initial effectiveness tests.